Walter Dettling
Presidente presso Inotech Biotechnologies AG
Posizioni attive di Walter Dettling
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Inotech Biotechnologies AG
 Inotech Biotechnologies AG Pharmaceuticals: MajorHealth Technology Inotech Biotechnologies AG specializes in research, development and production of biopharmaceuticals products. It helps people by creating apps and gadgets to reach their health and fitness goals. The company is headquartered in Basel, Switzerland. | Presidente | 04/12/2009 | - |
| Direttore/Membro del Consiglio | - | 04/12/2009 |
Storia della carriera di Walter Dettling
Precedenti posizioni note di Walter Dettling
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Vivendy Therapeutics Ltd.
 Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | Direttore/Membro del Consiglio | 10/01/2013 | 10/03/2014 |
Statistiche
Distribuzione geografica
| Svizzera | 3 |
Posizioni
| Director/Board Member | 2 |
| Chairman | 1 |
Settori
| Health Technology | 2 |
| Health Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Inotech Biotechnologies AG
Inotech Biotechnologies AG Pharmaceuticals: MajorHealth Technology Inotech Biotechnologies AG specializes in research, development and production of biopharmaceuticals products. It helps people by creating apps and gadgets to reach their health and fitness goals. The company is headquartered in Basel, Switzerland. | Health Technology |
Vivendy Therapeutics Ltd.
Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | Health Services |
- Borsa valori
- Insiders
- Walter Dettling
- Esperienza
